MEN1 and leukemia: Another class of clinically available molecules that show synergy with Menin inhibitors in KMT2A‐rearranged and NPM1 mutant leukemia are immunomodulatory drugs (IMIDs), like Lenalidomide, Pomalidomide or Mezigdomide.116, 128